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Abstract
In high-density myoblast cultures S100B enhances basic fibroblast growth factor (bFGF) receptor 1 (FGFR1) signaling via
binding to bFGF and blocks its canonical receptor, receptor for advanced glycation end-products (RAGE), thereby
stimulating proliferation and inhibiting differentiation. Here we show that upon skeletal muscle injury S100B is released
from myofibers with maximum release at day 1 post-injury in coincidence with satellite cell activation and the beginning of
the myoblast proliferation phase, and declining release thereafter in coincidence with reduced myoblast proliferation and
enhanced differentiation. By contrast, levels of released bFGF are remarkably low at day 1 post-injury, peak around day 5
and decline thereafter. We also show that in low-density myoblast cultures S100B binds RAGE, but not bFGF/FGFR1 thereby
simultaneously stimulating proliferation via ERK1/2 and activating the myogenic program via p38 MAPK. Clearance of S100B
after a 24-h treatment of low-density myoblasts results in enhanced myotube formation compared with controls as a result
of increased cell numbers and activated myogenic program, whereas chronic treatment with S100B results in stimulation of
proliferation and inhibition of differentiation due to a switch of the initial low-density culture to a high-density culture.
However, at relatively high doses, S100B stimulates the mitogenic bFGF/FGFR1 signaling in low-density myoblasts, provided
bFGF is present. We propose that S100B is a danger signal released from injured muscles that participates in skeletal muscle
regeneration by activating the promyogenic RAGE or the mitogenic bFGF/FGFR1 depending on its own concentration, the
absence or presence of bFGF, and myoblast density.
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Introduction
The regenerative capacity of skeletal muscle tissue resides in
satellite cells, the quiescent adult stem cells located between the
sarcolemma of the myofiber and the basal lamina [1,2]. In case of
intense physical exercise, trauma or systemic disorders such as
infectious diseases, cancer and chronic inflammatory diseases,
satellite cells become activated exiting their quiescence status,
emigrating and proliferating. Subsequently, activated satellite cells
stop proliferating and differentiate into fusion-competent myocytes
that form multinucleated syncytia called myotubes, the immediate
precursors of myofibers. Proliferation of activated satellite cells is a
fundamental step of the muscle regeneration process serving the
function of expanding the population of myoblasts and of
reconstituting the pool of reserve satellite cells. Conceivably,
interference with any one of the above steps will result in defective
muscle regeneration capacity. Thus, stimuli and/or conditions
that keep satellite cells proliferating will delay or impede muscle
regeneration because proliferation and differentiation are mutually
exclusive. On the other hand, inhibition of proliferation reduces
myoblast numbers and, hence, the number and size of regenerated
myofibers as well as the satellite cell reserve pool, and precocious
myoblast differentiation results in the formation of (a reduced
number of) thin myofibers.
The regeneration of injured muscle tissue requires an ordered
activation/inactivation of transcription factors, of which some are
muscle-specific (i.e., Myf5, MyoD, myogenin and MRF4) while
others (e.g., Pax7, NF-kB, b-catenin, serum response factor) are
not [1,2]. These transcription factors are regulated in part by
extracellular factors acting in a receptor-mediated manner.
Extracellular factors orchestrating muscle regeneration are
released by the injured myofibers themselves and by macrophages
and lymphocytes infiltrating the injured tissue.
S100B is a member of a multigenic family of Ca
2+-binding
proteins of the EF-hand type that are only expressed in
vertebrates, and exerts regulatory effects both as an intracellular
factor and as an extracellular signal [3]. As an extracellular
signal, S100B affects functions of several cell types via
engagement of the multiligand receptor for advanced glycation
end-products (RAGE), a member of the immunoglobulin
superfamily [4–6]. S100B is expressed in skeletal muscle tissue
[7,8], is found in crushed muscle extract [9], and stimulates
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11]. However, although myoblasts express RAGE [10], S100B
exerts its effects on myoblasts in vitro in a RAGE-independent
manner, enhancing basic fibroblast growth factor (bFGF)
receptor 1 (FGFR1) activity via binding to bFGF [9]. Interest-
ingly, RAGE is not expressed in mature skeletal myofibers [12],
becomes rapidly expressed in activated satellite cells upon muscle
injury and is repressed at completion of regeneration [13]
pointing to a physiological role of this receptor in muscle
regeneration. When activated by its ligand, high mobility group
box 1 (HMGB1) [14,15], RAGE transduces a promyogenic and
anti-proliferative and anti-tumor signal in cells of the myogenic
lineage [12,16,17], and deletion of Rage results in delayed
regeneration following injury, elevated satellite cell numbers,
reduced myofiber numbers and myofiber hypertrophy [13].
However, S100B does bind to RAGE in myoblasts and recruits it
into a RAGE/S100B/bFGF/FGFR1 tetracomplex resulting in
enhancement of bFGF/FGFR1 signaling and blockade of RAGE
promyogenic signaling [9].
The process of mouse skeletal muscle regeneration after injury
consists of sequential steps such as satellite cell activation, which
starts a few hours after injury and proceeds for 24–36 h;
proliferation of activated satellite cells, which starts during day 2
post-injury and proceeds for ,3 days; myoblast differentiation,
which starts at day 3 post-injury and proceeds for ,2 weeks; and
myofiber maturation, which starts at day 5 post-injury and is
complete by day 21–28 post-injury [18]. Use of myoblast cell lines
and primary myoblasts proved essential for quantitative analyses of
effects of the extracellular factors and receptors involved in the
regulation of satellite cell activation and myoblast proliferation and
differentiation. Analyses of myoblast differentiation are usually
performed using confluent, i.e. high-density (HD) cells, a condition
that allows the formation of a relatively large number of myotubes
in 3–4 days in differentiation medium (DM). However, this in vitro
condition might not reflect precisely the very beginning of the
regeneration process in vivo: whereas myoblast proliferation starts
soon after activation of satellite cells [18], proliferating myoblasts
are intermingled with macrophages and lymphocytes whose
presence might limit myoblast-myoblast contacts thus reducing
local myoblast density.
We show here that injured muscle tissue releases S100B, bFGF
and HMGB1 with different time courses: S100B is maximally
released at day 1 post-injury, bFGF is minimally released at day 1
post-injury peaking at day 5, and HMGB1 is released starting at
day 3 post-injury peaking between days 7 and 14. We also show
that in low-density (LD) myoblast cultures and as long as the
myoblast density is low, S100B (in the 0.1–1 nM range) interacts
with and activates RAGE, but not bFGF/FGFR1 and simulta-
neously stimulates proliferation and activates the myogenic
program; washing out S100B after 24 h of treatment results in a
faster decrease in the proliferation rate and a higher level of
differentiation during the next 24 h compared with S100B-
untreated myoblasts. By contrast, prolonging the treatment of
LD myoblasts with S100B for 3 or more days results in stimulation
of proliferation and inhibition of differentiation as a result of a
switch of the initial LD culture to an HD culture and consequent
formation of the RAGE/S100B/bFGF/FGFR1 tetracomplex.
However, raising the S100B dose to 100 nM in LD myoblast
cultures results in activation of bFGF/FGFR1 and RAGE
blockade, provided bFGF is present. Thus, S100B differentially
activates RAGE and bFGF/FGFR1 depending on its own
concentration, the presence or absence of bFGF, and myoblast
density. We discuss these results in the context of the muscle
regeneration process.
Results
S100B is Found in Conditioned Medium from Injured
Skeletal Muscle Tissue
To have a more detailed picture of leakage of S100B from
injured muscle tissue we collected the conditioned medium (CM)
from muscles at varying time points after injury and measured
S100B therein. We extended our analyses to released bFGF and
HMGB1. We found that levels of S100B in CM from injured
muscles amounted to ,21 ng/muscle at day 1 post-injury, i.e. in
coincidence with satellite cell activation, remaining relative high
(i.e., ,10 ng/muscle) during the next 4 days post-injury, i.e.
during the satellite cell proliferation and differentiation phases,
and declining to ,3 ng/muscle at day 7 post-injury, i.e. during
late myoblast differentiation phase, and to control values by day 14
post-injury, i.e. by the end of the myoblast differentiation process
(Fig. 1A). The high level of S100B detected at day 1 post-injury
likely reflected leakage of the protein from injured myofibers
whereas the lower though relatively high levels found during the
next 6 days might reflect ongoing clearance of leaked S100B and/
or diminishing S100B leakage consequent to myofiber repair.
Indeed, myofibers, quiescent satellite cells and proliferating
myoblasts express S100B [7–9], and a subset of S100B
+
lymphocytes [19] infiltrating the injured tissue might secrete the
protein as well. By contrast, levels of bFGF amounted to ,3 ng/
muscle at day 1 post-injury, peaked (,23 ng/muscle) at day 5 and
declined to control levels between days 7 and 14 post-injury
(Fig. 1A). HMGB1 was not detectable in CM at day 1 post-injury
and accumulated during the next days remaining high till day 14
post-injury (Fig. 1A). Using the tissue remaining after collection of
CM, we found that RAGE was not expressed in uninjured muscle
tissue whereas it was expressed during the day 1 to 14 post-injury
interval with a peak at day 5 (Fig. 1B), and it was localized to
activated satellite (Pax7
+) cells after injury (Fig. 1C). Also, FGFR1
was highly expressed at days 1, 3 and 5 post-injury declining
thereafter (Fig. 1B). Thus, at the time of satellite cell activation
injured muscle tissue released high amounts of S100B, very small
amounts of bFGF, and no HMGB1, and RAGE was expressed
early after injury and FGFR1 accumulated coincidently with
S100B release but in advance of bFGF release (Fig. 1A,B).
Given the time-course of S100B, bFGF and HMGB1 release
from injured muscles (Fig. 1A), the time-course of satellite cell
proliferation and differentiation following muscle injury [18], and
the transient expression of RAGE in activated, proliferating and
differentiating satellite cells in injured muscles ([13]; also see
Fig. 1B), we analyzed potential RAGE-mediated effects of S100B.
For quantitative analyses we used C2C12 myoblasts, an
established model of activated satellite cells, and primary
myoblasts isolated from neonatal wild-type (WT) and Rage
2/2
mice.
S100B Effects on Myoblast Differentiation Vary
Depending on Cell Density and the Duration of
Treatment
As mentioned in Introduction, S100B stimulates proliferation
and inhibits differentiation in HD myoblast cultures by enhancing
bFGF/FGFR1 signaling [9]. To mimic the situation found early
after muscle injury, i.e. when the population and/or the local
density of proliferating satellite cells are relatively small, we seeded
myoblasts at a low (i.e., ,86103 cells/cm
2) density in growth
medium (GM) for 24 h and then switched the cultures to DM for
24 h plus or minus S100B and for another 24 h to DM without
S100B. At the end of this treatment, S100B-treated LD cultures
showed enhanced myotube formation (Fig. 2A), increased levels of
RAGE and bFGF/FGFR1 in S100B Effects in Myoblasts
PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e28700Figure 1. S100B, bFGF and HMGB1 are released from injured muscles. (A) CM from uninjured or BaCl2-injured Tibialis anterior muscles were
processed for detection of S100B, bFGF and HMGB1 by Western blotting. S100B, bFGF and HMGB1 in CM were quantified by comparing the density
of individual western blot bands in the CM with that of increasing amounts of each purified protein in parallel western blots. (B) After collection of
CM, muscle tissue was homogenized and subjected to Western blotting for detection of RAGE and FGFR1 (20 mg protein loaded/lane). For
experiments in A and B three animals/time point were used and the whole experiment was performed two times. Results in A and B are expressed as
means 6 SD. C, Freshly excised uninjured or BaCl2-injured Tibialis anterior muscles were processed for detection of Pax7 and RAGE by double-
immunofluorescence. Nuclei were counterstained with DAPI. RAGE is not expressed in uninjured tissue. Arrow points to a quiescent satellite (Pax7
+)
cell (a,a9) and to a Pax7
+/RAGE
+ myoblast outside regenerating myofibers (b,b9). Arrowhead points to a Pax7
+/RAGE
+ myoblast within a regenerating
myofiber (b,b9). Bars=100 mm.
doi:10.1371/journal.pone.0028700.g001
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cadherin and caveolin-3, that are known to be required for
myoblast fusion [20–22] (Fig. 2B), and increased levels of the early
myogenic marker, myogenin (Fig. 2C), compared with controls.
Notably, when this experiment was performed using bFGF instead
of S100B, inhibition of differentiation was obtained (Fig. 2D),
suggesting that in LD myoblast cultures S100B might not enhance
bFGF/FGFR1 signaling, i.e. that S100B and bFGF might activate
different receptors. Contrary to HD myoblasts in which S100B
activated ERK1/2 and inhibited p38 MAPK [9], in LD cultures
S100B activated both, ERK1/2 and p38 MAPK, during the 24-h
treatment (Fig. 2E), and treatment of cultures with SB203580, a
specific inhibitor of the promyogenic p38 MAPK [23–27],
inhibited myogenin expression in S100B-treated and control
cultures (Fig. 2C), as expected. In contrast, PD98059, a specific
inhibitor of the mitogenic MEK-ERK1/2, stimulated myogenin
expression to a similar extent in S100B-treated and control LD
cultures (Fig. 2C) as expected [28]. A short-term treatment of LD
primary mouse myoblasts with S100B also resulted in enhanced
myogenin expression and myotube formation after S100B washout
Figure 2. S100B effects on differentiation vary depending on myoblast density and the duration of treatment with S100B. (A)L D
myoblasts were cultivated in DM in the absence or presence of S100B for 24 h, washed and cultivated for another 24 h in DM with no additions
before MyHC immunostaining. (B) Same as in A except that LD myoblasts were subjected to Western blotting for detection of MyHC, M-cadherin and
caveolin-3 at 24 h after washout (n=3). (C) LD C2C12 myoblasts were cultivated for 1 h in DM with the p38 inhibitor, SB203580 (2 mM) or the MEK-
ERK1/2 inhibitor, PD90059 (20 mM) and then for 24 h in the absence or presence of S100B, and subjected to Western blotting at 24 h after washout
using anti-myogenin antibody (n=3). (D) Same as in A except that LD myoblasts were treated with bFGF for 24 h and immunostained for MyHC at 24
and 48 h after bFGF washout. (E) LD myoblasts were cultivated in DM for 1, 24 or 72 h in the absence or presence of S100B and analyzed for ERK1/2
and p38 phosphorylation by Western blotting (n=3). (F) LD myoblasts were cultivated in DM for 72 h in the absence or presence of S100B and
subjected to MyHC immunostaining. *Significantly different from control.
#Significantly different from internal control. Bars=100 mm (A,F).
doi:10.1371/journal.pone.0028700.g002
RAGE and bFGF/FGFR1 in S100B Effects in Myoblasts
PLoS ONE | www.plosone.org 4 January 2012 | Volume 7 | Issue 1 | e28700(Fig. S1). Collectively, these results suggested that S100B-
dependent stimulation of bFGF/FGFR1 activity might not be
the mechanism underlying S100B effects in LD myoblasts.
However, chronic treatment of LD myoblasts with S100B caused
stimulation of ERK1/2 and inhibition of p38 MAPK (Fig. 2E) and
inhibition of differentiation (Fig. 2F) similar to HD myoblasts [9].
At Early Differentiation Stages S100B Exerts Mitogenic
Effects in LD and HD Myoblasts and Activates the
Myogenic Program in LD Myoblasts
S100B increased myoblast numbers and proliferation in both,
LD and HD cultures in DM (Fig. 3A,B). Smaller cell numbers
were measured in LD and HD cultures treated with PD98059,
compared with controls, and S100B was without effects under
these conditions (Fig. 3A,B). By contrast, treatment with
SB203580 increased the cell number in control cultures, and
S100B further increased it in HD but not LD cultures (Fig. 3A,B).
Thus, the ability of S100B to activate p38 MAPK in LD
myoblasts, as opposed to the inhibitory effect of the protein on
p38 MAPK in HD myoblasts [9], might serve a function other
than stimulation of proliferation. In the presence of PD98059 plus
SB203580, cell numbers decreased in control LD and HD cultures
likely due to inhibition of MEK-ERK1/2, and S100B was without
effects (Fig. 3A,B). Collectively, these results suggested that the
ability of S100B to promote myoblast proliferation in LD and HD
cultures in DM relied on stimulation of MEK-ERK1/2 and that
the inability of S100B to stimulate proliferation in SB203580-
treated LD myoblasts might be dependent on lack of S100B-
dependent enhancement of bFGF/FGFR1 activity in this
condition.
Cell counts of LD myoblast cultures in DM showed that S100B
significantly increased cell numbers at the end of the 24-h
treatment compared with controls (i.e., ,135 cells/field vs. ,70
Figure 3. At early differentiation stages S100B exerts mitogenic effects in LD and HD myoblasts and activates the myogenic
program in LD myoblasts. (A) LD and HD myoblasts were cultivated for 24 h in DM in the absence or presence of S100B plus or minus 20 mM
PD98059, 2 mM SB203580 or both before cell counts. (B) Parallel cells cultivated for 24 h in DM in the absence or presence of S100B were subjected to
BrdU incorporation assay. (C) LD myoblasts were cultivated for 24 h in DM in the absence or presence of S100B and either subjected to BrdU
incorporation assay or washed and cultivated in DM for another 24 or 48 h without additions before BrdU incorporation assay. Results are expressed
as cell numbers/field (top panel) and percentages of BrdU+ cells (bottom panel). (D) LD myoblasts cultivated for 24 h in DM in the absence or
presence of S100B plus or minus 20 mM PD98059 or 2 mM SB203580 were subjected to RT-PCR to detect myogenin mRNA. *Significantly different
from control. **Significantly different from control (first column from left) and internal control.
doi:10.1371/journal.pone.0028700.g003
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vehicle washout cell numbers were higher in S100B-treated and
untreated cultures compared with their respective controls;
however the percent increment was larger in the case of control
cultures than in S100B-treated cultures (Fig. 3C, top panel)
pointing to a lower proliferation rate of S100B-treated myoblasts
compared with controls after washout. Indeed, by a BrdU
incorporation assay (Fig. 3C, bottom panel) of control LD cultures
we found that ,22%, 18% and 15% of the cells were in the S
phase of the cell cycle at the end of the first 24-h in DM and at
24 h and 48 h after vehicle washout, respectively, while in S100B-
treated cultures ,39%, 22% and 12% of the cells were in S phase,
respectively. Thus, S100B increased the fraction of proliferating
myoblasts and total cell numbers during the 24-h treatment of LD
cultures, and both S100B-treated and control myoblasts reduced
their proliferation rate after vehicle/S100B washout. However, a
larger and faster reduction of the proliferation rate occurred in
S100B-treated than in control cells after washout. Also, at the end
of the 24-h treatment, S100B-treated myoblasts showed a ,90%
increase in myogenin mRNA compared with controls, and
inhibition of p38 MAPK resulted in similar and low myogenin
mRNA levels whereas inhibition of ERK1/2 resulted in enhanced
myogenin mRNA levels in S100B-treated and control myoblasts
(Fig. 3D) as expected [28]. These results suggested that in LD
myoblasts S100B increased the cell number via stimulation of
MEK-ERK1/2 and activated the myogenic program via stimu-
lation of p38 MAPK, and that the combination of these two events
determined an enhanced differentiation after S100B washout,
compared with controls.
S100B Activates RAGE, but not bFGF/FGFR1 in LD
Myoblasts
The different outcomes of short-term treatment of LD and HD
myoblasts with S100B appeared to be dependent mostly on the
different effect of the protein on p38 MAPK during the first 24 h
of treatment: stimulation in LD cultures (Fig. 2E) and inhibition in
HD cultures [9]. We reported that in HD myoblast cultures S100B
promotes the formation of a RAGE/S100B/bFGF/FGFR1
tetracomplex resulting in enhancement of bFGF/FGFR1 signaling
and blockade of RAGE signaling and, hence, in stimulation of
ERK1/2 and proliferation and inhibition of p38 MAPK and
differentiation [9].
In LD myoblasts, neutralization of FGFR1 resulted in decreased
basal ERK1/2 phosphorylation levels and increased basal p38
MAPK phosphorylation levels, and S100B activated both kinases
akin to native conditions (Fig. 4A). In this condition basal
proliferation and differentiation were significantly reduced, and
S100B stimulated proliferation and, after washout, differentiation
(Fig. 4B,C). The decreased basal differentiation of anti-FGFR1-
treated LD myoblasts might be due in part to the significant
reduction in the myoblast number consequent to reduced
proliferation (Fig. 4B), which further reduced the cell-cell contacts
required for fusion into myotubes and for N-cadherin-mediated
activation of the promyogenic p38 MAPK [29]. On the other
hand, S100B-induced enhancement of differentiation of anti-
FGFR1-treated LD myoblasts might be due to S100B ability to
activate the promyogenic p38 MAPK RAGE-dependently in this
condition (Fig. 4A). In the presence of anti-RAGE antibody no
major changes in basal ERK1/2 and p38 MAPK phosphorylation
levels compared with controls were detected, and S100B
stimulated ERK1/2 and inhibited p38 MAPK (Fig. 4A), and
stimulated proliferation (Fig. 4B) and inhibited differentiation
(Fig. 4C,D) similar to HD myoblasts under native conditions [9].
Thus, we tentatively concluded that short-term treatment of LD
myoblasts with S100B resulted in activation of RAGE, but not
bFGF/FGFR1, in contrast to activation of bFGF/FGFR1 but not
RAGE in HD myoblasts. However, blocking RAGE in LD
cultures made S100B able to activate bFGF/FGFR1 as inferred by
the S100B-dependent enhancement of proliferation and reduction
of differentiation in this condition (Fig. 4B,D; also see Fig. 5B).
RAGE, but not bFGF/FGFR1 Co-immunoprecipitates with
S100B in LD Myoblasts at Early Differentiation Stages
Whereas in HD myoblast cultures RAGE and FGFR1 co-
immunoprecipitated with S100B [9], in LD cultures RAGE, but
not FGFR1 co-immunoprecipitated with S100B, and S100B co-
immunoprecipitated with RAGE but not FGFR1 (Fig. 5A). In the
absence of added S100B a certain amount of the protein was
found in S100B immunoprecipitates (Fig. S2A) likely reflecting the
presence of the protein in commercial sera [10], and adding
S100B (1 nM) to myoblast cultures resulted in larger amounts of
the protein in S100B immunoprecipitates (Fig. S2A) as expected.
Also, bFGF was present in culture media of LD myoblasts
cultivated for 30 min in DM in the absence or presence of added
S100B (Fig. S2B). As in the case of HD myoblast cultures [9] no
Met was detected in the S100B immunoprecipitate (Fig. 5A)
indicating that effects of S100B on LD myoblasts were not
mediated by the hepatocyte growth factor receptor, Met, either.
No S100B or bFGF co-immunoprecipitated with bFGF or S100B,
respectively, in LD myoblasts (Fig. 5A). Accordingly, FGFR1 was
not found in S100B immunoprecipitates (Fig. 5A), S100B was not
found in FGFR1 immunoprecipitates (Fig. 5A), and no S100B-
dependent increase in FGFR1 phosphorylation (activation) levels
could be observed (Fig. 5B) in contrast to the S100B-induced
enhancement of FGFR1 phosphorylation levels in the presence of
bFGF in HD myoblasts [9]. Thus, at early differentiation stages of
LD myoblast cultures S100B bound to and engaged RAGE
thereby simultaneously stimulating the mitogenic ERK1/2 and
the promyogenic p38 MAPK: S100B/RAGE-dependent activa-
tion of ERK1/2 resulted in stimulation of proliferation whereas
S100B/RAGE-dependent activation of p38 MAPK resulted in
activation of the myogenic program. However, neutralizing
RAGE in LD myoblasts resulted in co-immunoprecipitation of
bFGF and FGFR1 with S100B (Fig. 5C) and enhancement of
FGFR1 phosphorylation (Fig. 5B,C).
As a long-term treatment of LD cultures with S100B caused
inhibition of differentiation (Fig. 2E), we performed immunopre-
cipitation analyses using LD cultures exposed to S100B for 3 days.
Under this condition RAGE, bFGF and FGFR1 co-immunopre-
cipitated with S100B (Fig. 5D) similar to HD myoblasts [9]. This
latter result was likely due to the S100B-dependent switch of the
initial LD culture to an HD culture: indeed, treatment of LD
cultures for 3 days with S100B resulted in a ,3-fold increase in the
cell number (Fig. 5E).
Given the multiligand nature of RAGE, we asked whether
another RAGE activator, i.e. HMGB1 [14,15], exerted the same
effects in LD myoblasts as did S100B. HMGB1 was shown to exert
promyogenic and anti-proliferative effects via RAGE ligation in
HD myoblasts [12,16], and to promote muscle regeneration when
infused into dystrophic [30] or ischemic [31] muscle tissue. During
the first 24 h of treatment HMGB1 activated ERK1/2 and p38
MAPK (Fig. S3A), stimulated proliferation (Fig. S3B) and
activated the differentiation program (Fig. S3C) as did S100B.
At 24 h after washout HMGB1-treated myoblasts expressed
higher MyHC levels than untreated myoblasts (Fig. S3D). Also,
RAGE, but not FGFR1 co-immunoprecipitated with HMGB1
(Fig. S3E), and HMGB1 did not co-immunoprecipitate with either
bFGF, S100B or FGFR1 irrespective of myoblast density
RAGE and bFGF/FGFR1 in S100B Effects in Myoblasts
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not identical mechanism of action of S100B and HMGB1 in LD
myoblasts while establishing a fundamental difference between
these two RAGE ligands in HD myoblasts.
At High Doses S100B Promotes the Formation of a RAGE/
S100B/bFGF/FGFR1 Tetracomplex in LD Myoblasts at
Early Differentiation Stages
Next we asked why S100B was unable to activate bFGF/
FGFR1 in LD myoblast cultures at early differentiation stages. At
24 h after the switch to DM, LD culture media contained ,3-
times higher bFGF levels than HD culture media (Fig. 6A)
pointing to differential secretion of bFGF by C2C12 myoblasts
depending on cell density. However, despite the relatively high
levels of bFGF in LD culture media, no S100B-dependent
stimulation of bFGF/FGFR1 signaling or S100B/bFGF/FGFR1
complex formation occurred (Figs. 5A–C). Yet, when LD cultures
were treated with a 100-times higher (i.e., 100 nM vs. 1 nM)
S100B dose, RAGE, bFGF and FGFR1 were detected in S100B
immunoprecipitates (Fig. 6B), and stimulation of proliferation and
reduction of MyHC levels were observed at 24 h after S100B
washout (Fig. 6C) along with stimulation of FGFR1 phosphory-
lation (Fig. 6D) akin to HD cultures treated with 1 nM S100B [9].
But, when the immunoprecipitation assay was performed using
LD cultures pretreated with a bFGF neutralizing antibody and
exposed to 100 nM S100B, RAGE but essentially no FGFR1 or
bFGF was detected in S100B immunoprecipitates (Fig. 6E). Thus,
in LD myoblasts a RAGE/S100B/bFGF/FGFR1 tetracomplex
formed at high S100B doses and for this to occur the presence of
bFGF was required whereas in the absence of bFGF S100B
invariably bound to RAGE. The simplest explanation for the
different results obtained with low and high S100B in LD
myoblasts was that S100B has a higher binding affinity to RAGE
than to bFGF/FGFR1 and/or that the larger amount of high-
order S100B oligomers forming at high S100B concentrations
compared with low concentrations [32,33] might cause S100B-
dependent cross-linking of RAGE and bFGF/FGFR1. As an
additional but not alternative possibility, at high doses S100B
might interact separately with RAGE and bFGF/FGFR1 in LD
myoblasts. We analyzed these possibilities by a combination of co-
immunoprecipitation and in situ proximity ligation assay (PLA)
[34].
By co-immunoprecipitation assay we found that upon treatment
of LD myoblasts with 100 nM S100B all binding partners, i.e.
S100B, bFGF, RAGE and FGFR1, were found in immunopre-
cipitates irrespective of whether anti-S100B, anti-bFGF, anti-
RAGE or anti-FGFR1 antibody was used to generate the
immunoprecipitates (Fig. 6F). Thus, at high doses S100B likely
Figure 4. S100B activates RAGE, but not bFGF/FGFR1 in LD
myoblasts. (A) LD myoblasts in DM were pretreated with non-immune
IgG, anti-RAGE antibody or anti-FGFR1 antibody (2 h) and cultivated for
24 h in the absence or presence of S100B. Cultures were subjected to
Western blotting to detect phosphorylated ERK1/2 and p38 (n=3). (B)
Same as in A except that cells pretreated with anti-RAGE or anti-FGFR1
antibody were cultivated for 24 h in the absence or presence of S100B
and processed for proliferation by a BrdU incorporation assay (n=3).
(C,D) Same as in B except that cells pretreated with anti-RAGE or anti-
FGFR1 antibody were cultivated for 24 h in the absence or presence of
S100B, washed and cultivated in DM for another 24 h without additions
and processed for MyHC immunostaining (C) or Western blotting of
MyHC (D) (n=3). *Significantly different from control (first column from
left).
#Significantly different from internal control. n=3. Bars=100 mm
(C).
doi:10.1371/journal.pone.0028700.g004
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tetracomplex in LD myoblasts at early differentiation stages in
contrast to lack of formation of such a complex at low S100 doses.
These differences were likely to depend on the larger amounts of
high-order S100B oligomers at 100 nM than at 1 nM [32,33]
given that all other experimental parameters were constant. By in
situ PLA, S100B/RAGE complexes were detected on myoblasts
when S100B was used at 1 nM, and a larger number of S100B/
RAGE complexes formed when S100B was used at 100 nM
(Fig. 6G). In accordance with the co-immunoprecipitation results
in 5A,C,D and 6B,E, no S100B-induced close association between
RAGE and FGFR1 could be detected in LD myoblasts treated
with 1 nM S100B (Fig. 6H), whereas such a close association was
observed in LD myoblasts treated with 100 nM S100B, provided
bFGF was present (Fig. 6H). Also in accordance with the co-
immunoprecipitation results in Figs. 5A and 6B, no S100B/bFGF
immunocomplex formation was detected when S100B was used at
1 nM, whereas S100B/bFGF complexes formed when S100B was
Figure 5. RAGE, but not bFGF/FGFR1 co-immunoprecipitates with S100B in LD myoblasts at early differentiation stages. (A)L D
myoblasts cultivated in DM for 30 min in the presence of 1 nM S100B were subjected to immunoprecipitation using anti-S100B, anti-FGFR1, anti-
bFGF or anti-RAGE antibody. The immunoprecipitates were subjected to Western blotting for detection of S100B, FGFR1, bFGF, or RAGE. In control
samples non-immune IgG (IP-IgG) were used. Twenty mg protein were loaded in input lanes. (B) LD myoblasts were cultivated in DM for 30 min in the
absence or presence of either 1 nM S100B or 1 nM bFGF after pretreatment with IgG (10 mg/ml) or anti-RAGE antibody (10 mg/ml). Cells were lysed
and cell lysates were subjected to Western blotting for detection of phosphorylated Tyr and FGFR1. (C) LD myoblasts cultivated in DM for 2 h in the
presence of either non-immune IgG (10 mg/ml) or anti-RAGE antibody (10 mg/ml). Cultures were then added with 1 nM S100B for 30 min and
subjected to immunoprecipitation using anti-S100B antibody. Immunoprecipitates were probed by Western blotting with anti-S100B, anti-FGFR1,
anti-bFGF or anti-RAGE antibody. The WB:FGFR1 filter was reprobed with anti- phosphorylated Tyr antibody (marked by the ‘‘[’’ symbol). (D)L D
myoblasts were cultivated in DM for 3 days in the presence of 1 nM S100B without medium renovation and subjected to immunoprecipitation using
anti-S100B antibody. The immunoprecipitates were probed by Western blotting with anti-S100B, anti-FGFR1, anti-bFGF or anti-RAGE antibody. (E)L D
myoblasts were cultivated in DM for 3 days in the presence of 1 nM S100B without medium renovation and counted. *Significantly different from
control.
doi:10.1371/journal.pone.0028700.g005
RAGE and bFGF/FGFR1 in S100B Effects in Myoblasts
PLoS ONE | www.plosone.org 8 January 2012 | Volume 7 | Issue 1 | e28700RAGE and bFGF/FGFR1 in S100B Effects in Myoblasts
PLoS ONE | www.plosone.org 9 January 2012 | Volume 7 | Issue 1 | e28700used at 100 nM (Fig. 6H). A relatively small number of bFGF/
FGFR1 immunocomplexes were detected under basal conditions
(i.e., in the absence of additions) (Fig. 6H) likely reflecting the
presence of a certain amount of bFGF in the culture medium
(Figs. 5A, IP:bFGF and S2B), with relatively large numbers being
observed upon addition of bFGF to 1 nM to the culture as
expected (Fig. 6H). Also, whereas relatively large numbers of
S100B/RAGE and S100B/bFGF immunocomplexes per myo-
blast were detected when S100B was used at 100 nM (Fig. 6H),
relatively small numbers of S100B/FGFR1 and of RAGE/FGFR1
immunocomplexes were detected in this same condition (Fig. 6H).
These latter results were consistent with the notion that S100B can
physically interact with RAGE and, under appropriate conditions,
FGFR1-bound bFGF, but not with FGFR1 [9], and pointed to a
longer distance between S100B and FGFR1 and between RAGE
and FGFR1 than between S100B and RAGE and between S100B
and bFGF in immunocomplexes (see [34] for a comprehensive
discussion of interpretation of in situ PLA results). Together, these
results suggested that the S100B binding affinity to RAGE is
higher than to bFGF/FGFR1 thus promoting the formation of
S100B/RAGE complexes and precluding the formation of
RAGE/S100B/bFGF/FGFR1 tetracomplexes in LD myoblast
culture treated with 1 nM S100B, and that at high concentrations
S100B might exist in the form of oligomers capable of cross-linking
RAGE and bFGF/FGFR1 in LD myoblasts (see Discussion).
We also found that a RAGE/S100B/bFGF/FGFR1 tetracom-
plex formed in LD cultures that had been scraped, suspended in
DM containing 1 nM S100B, centrifuged (to increase the extent of
cell-cell contacts), and subjected to co-immunoprecipitation using
anti-S100B antibody (Fig. 6G). This result suggested that: 1) the
low extent of cell-cell contacts in LD myoblasts might be one
major cause of lack of formation of the RAGE/S100B/bFGF/
FGFR1 complex when S100B was used at 1 nM strongly
suggesting that cell density was a crucial factor determining
whether low S100B activated RAGE or bFGF/FGFR1 in
myoblast cultures; 2) in HD myoblast cultures low S100B
promoted the formation of a RAGE/S100B/bFGF/FGFR1
transcomplex (i.e., a complex between RAGE on a cell and
bFGF/FGFR1 on an apposed cell) whereas in LD myoblast
cultures high S100B promoted the formation of a RAGE/S100B/
bFGF/FGFR1 ciscomplex (i.e., a complex between RAGE and
bFGF/FGFR1 on the same cell) (see Discussion); and 3) the
increase in the myoblast number in case of chronic treatment of
LD myoblasts with 1 nM S100B (Fig. 5E) created the conditions of
an HD culture thus allowing the formation of the RAGE/S100B/
bFGF/FGFR1 transcomplex.
In Vivo Formation of S100B/RAGE and RAGE/S100B/
bFGF/FGFR1 Complexes
By in situ PLA, no cells exhibiting S100B/RAGE or RAGE/
FGFR1 complexes could be seen in uninjured skeletal muscle
tissue (Fig. 7A). However, increasing numbers of mononucleated
cells exhibiting S100B/RAGE complexes were observed in skeletal
muscle tissue at day 1 to day 5 post-injury in coincidence with
relatively high and low S100B and bFGF levels, respectively, in
CM and high RAGE levels in tissue, and decreasing numbers at
days 7 and 14 post-injury in coincidence with very low S100B
levels in CM and still high RAGE levels in tissue (Fig. 1A,B).
Mononucleated cells exhibiting RAGE/FGFR1 complexes indic-
ative of RAGE/S100B/bFGF/FGFR1 tetracomplex formation
were seen in very low numbers at day 1 post-injury and increasing
numbers at days 3 and 5 post-injury (Fig. 7A). Notably, similar
numbers of mononucleated cells exhibiting S100B/RAGE and
RAGE/FGFR1 complexes were observed at day 4 post-injury
(Fig. 7B). Interestingly, at day 4 post-injury, i.e. when the density
of mononucleated cells between myofibers was relatively high,
RAGE/FGFR1 complexes were detected at contact sites of
apposed cells (Fig. 7A, day 4, arrows) besides on single cells,
whereas S100B/RAGE complexes were mostly seen on single
cells. These results supported the possibility that S100B preferen-
tially activates RAGE early after muscle injury (i.e., during the
activation/proliferation phase) and enhances bFGF/FGFR1
signaling during the myoblast proliferation phase in vivo.
However, it is possible that at single time-points during muscle
regeneration, there are sites where S100B-activated RAGE
signaling prevails over S100B-enhanced bFGF/FGFR1 signaling
and sites where the opposite occurs.
Low S100B Upregulates RAGE, but not FGFR1 Expression
in LD Myoblasts
We recently found [13] that: 1) RAGE is sharply expressed in
activated satellite cells following injury, is detected in Pax7
+/
myogenin
2 (i.e., proliferating) satellite cells (also see Fig. 1C) and
Figure 6. At high doses S100B promotes the formation of a RAGE/S100B/bFGF/FGFR1 tetracomplex in LD myoblasts at early
differentiation stages. (A) HD myoblasts (one dish) and LD myoblasts (four dishes) were cultivated in DM for 24 h. Culture media were collected
and subjected to Western blotting using anti-bFGF antibody. After collection of culture media the cells were lysed for Western blotting of tubulin. (B)
LD myoblasts were cultivated in DM for 30 min in the presence of 1 or 100 nM S100B and subjected to immunoprecipitation using anti-S100B
antibody. The immunoprecipitates were probed with anti-FGFR1, anti-RAGE or anti-bFGF antibody. (C) LD myoblasts were cultivated in DM for 24 h
in the presence of varying S100B concentrations and subjected to BrdU incorporation assay to measure proliferation at the end of the 24-h treatment
(upper panel). Parallel cells were washed after the first 24-h treatment, further cultivated in DM for 24 h without additions and subjected to Western
blotting for detection of MyHC (lower panel). (D) LD myoblasts were cultivated in DM for 30 min in the absence or presence of 100 nM S100B. Cells
were lysed and cell lysates were subjected to Western blotting for detection of pho-Tyr and FGFR1. (E) LD myoblasts were cultivated in DM for 2 h in
the presence of either 40 mg/ml non-immune IgG or 40 mg/ml anti-bFGF antibody followed by addition of vehicle or S100B to 100 nM for 30 min and
immunoprecipitation using anti-S100B antibody. The immunoprecipitates were probed with anti-bFGF, anti-FGFR1 or anti-RAGE antibody. (F)L D
myoblasts cultivated in DM for 30 min in the presence of 100 nM S100B were subjected to immunoprecipitation using anti-S100B, anti-FGFR1, anti-
bFGF or anti-RAGE antibody. The immunoprecipitates were subjected to Western blotting for detection of S100B, FGFR1, bFGF, or RAGE. (G)L D
myoblasts were cultivated in GM for 24 h, washed, scraped using PBS and collected by centrifugation. The pellet was resuspended in DM (5 ml, i.e.
the same volume as used during the cultivation in petri dishes) containing 1 nM S100B, centrifuged at 5006g for 5 min at room temperature and
incubated at 37uC for 30 min without aspiring the supernatant. By this procedure, cell-cell contacts of the original LD culture were augmented thus
artificially reproducing the conditions of an HD culture. The supernatant was aspired, and the pellet was resuspended in PBS containing 1 mM CaCl2
and centrifuged as above. The pellet was resuspended in 1 ml of lysis buffer for subsequent immunoprecipitation using anti-S100B antibody. The
immunoprecipitate was probed with anti-RAGE, anti-FGFR1, anti-S100B or anti-bFGF antibody. (H) Complex formation among S100B, bFGF, FGFR1
and RAGE in LD myoblasts as investigated by in situ proximity ligation assay (PLA). LD myoblasts in DM were incubated for 30 min with varying S100B
concentrations as indicated or with 1 nM bFGF. LD myoblasts in DM were also treated with either 5 mg/ml non-immune IgG or 5 mg/ml anti-bFGF
antibody followed by addition of vehicle or S100B to 100 nM for 30 min. Cells were then subjected to in situ PLA using antibody pairs as indicated on
top of panels. In control experiments one antibody of individual pairs was omitted as indicated. *Significantly different from control. Bars=20 mm (H).
doi:10.1371/journal.pone.0028700.g006
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PLoS ONE | www.plosone.org 10 January 2012 | Volume 7 | Issue 1 | e28700Figure 7. S100B/RAGE and RAGE/FGFR1 complexes in regenerating skeletal muscle tissue. (A) Uninjured and injured skeletal muscle
tissue was subjected to in situ PLA using anti-S100B/anti-RAGE antibody pairs (left) or anti-RAGE/anti-FGFR1 antibody pairs (right). Myofiber
boundaries in transverse sections are marked by dotted lines. No S100B/RAGE or RAGE/FGFR1 complexes can be detected in uninjured skeletal
muscle tissue. Arrows point to RAGE/FGFR1 complexes at apposed myoblasts. RAGE/FGFR1 complexes actually represent RAGE/S100B/bFGF/FGFR1 -
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2/myogenin
+ (i.e., differentiating) satellite cells during the
proliferation and differentiation phases, and is repressed at
completion of regeneration; 2) maximum RAGE expression levels
in injured muscle tissue are measured around day 5 post-injury
(also see Fig. 1B), i.e. in coincidence with decreasing proliferation
of activated satellite cells and increasing differentiation of
myoblasts [18]; and 3) regeneration of injured Rage
2/2 muscles
is delayed at least one week compared with wild-type muscles.
Collectively, these results suggest that RAGE signaling plays a
physiological role during regeneration of injured skeletal muscles.
Given the time-course of S100B release from injured muscles
(Fig. 1A) and considering that RAGE ligands upregulate RAGE
expression [4,5], we analyzed the possibility that S100B might
contribute to increase RAGE expression in LD myoblasts.
Indeed, S100B in the 1–10 nM range increased RAGE, but not
FGFR1 levels in LD myoblast cultures (Fig. S4A). However, when
added to 100 nM to LD myoblast cultures, S100B enhanced
FGFR1 levels while losing the ability to increase RAGE levels (Fig.
S4B). Low S100B upregulated RAGE expression in LD cultures in
a RAGE-dependent manner as no such effect occurred in LD
cultures pretreated with a RAGE neutralizing antibody (Fig. S4C).
Significantly, low S100B upregulated FGFR1 levels in LD cultures
pretreated with a RAGE neutralizing antibody (Fig. S4C) likely
due to the ability of S100B to enhance bFGF-FGFR1 signaling
under these conditions (see Figs. 4B,C and 5B,C).
S100B Engages RAGE in LD Primary Wild-type Myoblasts
and Activates FGFR1 in LD Rage
2/2 Myoblasts
S100B stimulated proliferation and inhibited differentiation of
HD WT and Rage
2/2 myoblasts via complex formation with
bFGF/FGFR1 [9]. Whereas in LD WT myoblasts RAGE, but not
FGFR1 or bFGF co-immunoprecipitated with low S100B
(Fig. 8A), in the case of LD Rage
2/2 myoblasts FGFR1 and
bFGF co-immunoprecipitated with low S100B (Fig. 8A) and
S100B enhanced FGFR1 phosphorylation (Fig. 8B) similar to LD
C2C12 myoblasts treated with anti-RAGE antibody (Fig. 5B,C).
Consistently, S100B enhanced the proliferation and was unable to
activate the differentiation program in LD Rage
2/2 myoblasts
(Fig. 8C). Also, clearance of S100B after 24 h resulted in
stimulation of myogenin expression in WT myoblasts, whereas
reduction of myogenin levels was observed in Rage
2/2 myoblasts
(Fig. 8D). Lastly, chronic treatment of WT and Rage
2/2 myoblasts
see text). Bars=200 mm. (B) Quantitative analysis of the distribution of S100B/RAGE and RAGE/FGFR1 complexes in uninjured skeletal muscle tissue
and at the indicated days post-injury. In situ complexes were counted in 10 fields (620 magnification)/section in a total of 10 sections/time point
from 2 animals. *Significantly different.
doi:10.1371/journal.pone.0028700.g007
Figure 8. S100B engages RAGE in LD wild-type myoblasts and activates FGFR1 in Rage
2/2 myoblasts. (A) Primary myoblasts from WT
and Rage
2/2 mice in DM were treated for 30 min with 1 nM S100B and subjected to immunoprecipitation using an anti-S100B antibody. S100B
immunoprecipitates were analyzed for RAGE, FGFR1, bFGF and c-Met levels. (B) LD WT and Rage
2/2 myoblasts were cultivated in DM for 30 min in
the absence or presence of either 1 nM S100B or 1 nM bFGF. Cells were lysed and cell lysates were subjected to Western blotting for detection of
phosphorylated Tyr and FGFR1. (C) WT and Rage
2/2 myoblasts cultivated in DM for 24 h in the absence or presence of 1 nM S100B were subjected to
BrdU incorporation assay. (D) WT and Rage
2/2 myoblasts were cultivated in DM in the absence or presence of 1 nM S100B for 24 or 72 h without
medium renewal. One set of cells was washed and further cultivated for 48 h in DM without additions. At the end of treatments, cells were lysed and
cell lysates were subjected to Western blotting to detect myogenin (as a myogenic differentiation marker). *Significantly different from control (first
column from left).
#Significantly different from internal control (second column from left).
doi:10.1371/journal.pone.0028700.g008
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Thus, absence of RAGE made S100B available for binding to
bFGF/FGFR1 irrespective of the cell density (also see [9]), again
suggesting that a higher binding affinity of S100B to RAGE than
to bFGF/FGFR1 might play an important role in S100B effects in
LD WT myoblast cultures.
Discussion
We have shown that the danger signal S100B protein is released
in high abundance from injured skeletal muscle tissue at day 1
post-injury, and levels of released S100B remain relatively high
during the next 4 days, declining around day 7 post-injury and
diminishing to control values by day 14. Thus, relatively high
levels of extracellular S100B are found in injured muscles during
the satellite cell activation and proliferation phases followed by a
slow decrease during the myoblast differentiation phase and no
obvious release during the myofiber maturation phase. The time-
course of S100B release upon muscle injury and levels of released
S100B point to regulatory effects of the protein during the satellite
cell activation, proliferation and early differentiation phases, with
the potential of activating bFGF/FGFR1 [9] or RAGE (the
present study) depending on local S100B and bFGF concentra-
tions and myoblast density and on levels of RAGE expression.
Importantly, however, very low levels of bFGF are found in CM
from injured muscles early after injury (Fig. 1A), whereas RAGE
becomes rapidly expressed in activated satellite cells (Fig. 1C).
Thus, during the first few days post-injury S100B might activate
RAGE irrespective of S100B concentration and myoblast density
given the very small release of bFGF, and activate bFGF/FGFR1
thereafter in coincidence with maximum release of bFGF, high
FGFR1 levels and a higher myoblast density.
Using C2C12 and primary myoblasts as a model we have
shown that in LD myoblast cultures low S100B engages RAGE
thereby simultaneously stimulating proliferation via MEK-ERK/2
and activating the myogenic program via p38 MAPK. These
results are at variance with those obtained using HD myoblast
cultures in which low S100B stimulates bFGF/FGFR1 signaling
and inactivates RAGE via the formation of a RAGE/S100B/
bFGF/FGFR1 tetracomplex thereby enhancing myoblast prolif-
eration and inhibiting myogenic differentiation [9]. The afore-
mentioned S100B effects on LD myoblasts are restricted to the first
24 h of treatment in DM and result in different outcomes beyond
this time interval depending on whether or not S100B persists:
clearance of S100B results in a larger and faster decrease in the
proliferation rate and in an enhanced myotube formation
compared with controls consequent to S100B-induced increase
in myoblast density and activation of the myogenic program,
whereas maintaining S100B in the culture medium results in
stimulation of proliferation and inhibition of differentiation as a
consequence of S100B-dependent switch of the initial LD culture
to an HD culture.
In LD cultures and as long as the myoblast density is low, low
S100B cannot bind to bFGF/FGFR1 thus precluding the
enhancement of FGFR1 signaling; S100B binding to RAGE in
this condition causes stimulation of proliferation via ERK1/2 and
upregulation of myogenin mRNA expression via p38 MAPK that
translate into enhanced myogenic differentiation once S100B has
been cleared. However, high S100B can promote the formation of
a RAGE/S100B/bFGF/FGFR1 tetracomplex in LD cultures
resulting in stimulation of proliferation and inhibition of
differentiation. As the RAGE and FGFR1 abundance on a per
cell basis at the time of switch from GM to DM was the same in
LD and HD myoblast cultures (unpublished data), the inability of
low S100B to interact with bFGF/FGFR1 in LD myoblasts is
likely to depend on a higher binding affinity of the protein to
RAGE than to bFGF/FGFR1. This conclusion is supported by
the finding that, as investigated by co-immunoprecipitation assay
and in situ PLA, increasing the S100B dose to 100 nM makes
S100B capable of recruiting RAGE and bFGF/FGFR1 into a
complex in LD in myoblasts at early differentiation stages resulting
in stimulation of MEK-ERK1/2 and proliferation and inhibition
of p38 MAPK and differentiation. Results obtained using C2C12
myoblasts pretreated with a RAGE neutralizing antibody and
Rage
2/2 myoblasts are consistent with this conclusion: in the
absence of functional RAGE, S100B interacts with bFGF/FGFR1
irrespective of myoblast density thereby enhancing the mitogenic
and anti-myogenic bFGF/FGFR1 signaling. However, for this to
occur the presence of bFGF is required: in the absence of bFGF
S100B activates the promyogenic RAGE irrespective of the S100B
concentration and myoblast density (also see [9]).
Short-term treatment of LD C2C12 myoblasts with S100B
results in activation of ERK1/2 and p38 MAPK. Simultaneous
activation of ERK1/2 and p38 MAPK in myoblasts in DM is
counterintuitive given the established role of ERK1/2 in
stimulation of proliferation [29,35,36] and of p38 MAPK in
activation of the myogenic program [23–27]. The proposed role of
p38 MAPK as a molecular switch from proliferation to
differentiation in myoblasts [37] cannot be invoked in the present
case because we performed our experiments in DM and because
inhibition of p38 MAPK resulted in increased cell numbers and
inhibition of differentiation. Thus, the ability of S100B to cause
those apparently contrasting effects at early stages of differentia-
tion of LD myoblasts relies on the engagement of RAGE.
In the extracellular space, S100B forms oligomers [32,33], and
S100B causes RAGE oligomerization via binding to RAGE V
domain [33] and/or stabilizes RAGE oligomers [38], which is
required for RAGE signaling [39]. Based on the present results, we
propose that in LD cultures treated with low S100B, S100B
tetramers/octamers promote RAGE oligomerization and/or stabi-
lize RAGE oligomers resulting in RAGE activation (Fig. 9A, left
half, low S100B). By contrast, at high S100B concentrations higher-
order S100B oligomers might additionally interact with FGFR1-
bound bFGF resulting in the formation of a RAGE/S100B/bFGF/
FGFR1 on the same cell (Fig. 9A, left half, high S100B). In this case,
RAGE cannot efficiently oligomerize and, hence, cannot signal,
whilebFGF-FGFR1signalingisenhanced.However,intheabsence
of bFGF either low or high S100B activates RAGE (Fig. 8A, left
half). By contrast, in HD cultures treated with low S100B, S100B
tetramers/octamers might cross-link RAGE and FGFR1-bound
bFGF on apposed cells (Fig. 9A, right half) with resultant inability of
non-stabilized RAGE oligomers to activate p38 MAPK and
enhancement of bFGF-FGFR1 signaling.
RAGE activation by HMGB1 in HD myoblasts results in p38
MAPK-dependent stimulation of differentiation and inhibition of
proliferation via p38 MAPK-dependent inhibition of ERK1/2
[12,16]. By contrast, RAGE activation by HMGB1 in LD cultures
results in activation of both p38 MAPK and ERK1/2 at early
differentiation stages stimulating proliferation and activating the
myogenic program similar to S100B. However, with increasing
myoblast density HMGB1 stimulates differentiation and inhibits
proliferation [12,16]. Thus, HMGB1-induced ability of RAGE to
stimulate differentiation and inhibit proliferation in HD cultures,
as opposed to the inability of S100B to stimulate RAGE in this
condition, likely reflects the ability of S100B, but not HMGB1 to
bind bFGF/FGFR1. It is tempting to speculate that HMGB1-
induced activation of RAGE during the first 24 h in LD myoblasts
results in an extent of p38 MAPK activation sufficient to activate
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contrast, in HD myoblasts a more intense and sustained HMGB1/
RAGE-dependent activation of p38 MAPK might result in
inhibition of ERK1/2 [16]. Also, signals triggered by cell-cell
contacts in HD cultures might enhance p38 MAPK activity. For
example, in HD myoblast cultures N-cadherin signaling [29] and
activation of the immunoglobulin superfamily member, CDO
[40], activate p38 MAPK and the myogenic program, and these
effects might add to HMGB1/RAGE effects.
RAGE expression in skeletal muscle tissue is developmentally
regulated, RAGE being expressed up to a few postnatal days and
repressed thereafter [12]. RAGE becomes transiently re-expressed
in adult skeletal muscle satellite cells upon injury (Fig. 1B,C)
followed by repression of RAGE expression at completion of the
regeneration process, and RAGE expression and signaling in
activated satellite cells are required for optimal muscle regener-
ation. Indeed, muscle regeneration is delayed at least one week in
Rage
2/2 mice, RAGE signaling via p38 MAPK playing an
important role in the induction of myogenin and myogenin-
dependent repression of Pax7 expression [13]. In this context,
S100B released from injured myofibers might stimulate RAGE
signaling and even enhance RAGE expression in activated satellite
cells (Fig. 9B), thereby stimulating myoblast proliferation and
activating the myogenic program. This is a likely possibility early
after injury given the sharp release of S100B from injured
myofibers, the very small extent of bFGF release at day 1 post-
injury (Fig. 1A) and the rapid expression of RAGE in activated
satellite cells (Fig. 1B,C). However, during the proliferation phase
of the regeneration process [18] when both S100B and bFGF are
present extracellularly (Fig. 1A), S100B would promote the
expansion of the myoblast population by enhancing bFGF/
FGFR1 signaling (Fig. 8B): at this stage RAGE signaling would be
reduced owing to its recruitment into a RAGE/S100B/bFGF/
FGFR1 tetracomplex [9]. Yet, extracellular HMGB1, which also
accumulates in the extracellular space during the proliferation
phase and persists there longer than S00B and bFGF, might
compete with S100B for binding to RAGE [12] thereby unlocking
RAGE and enhancing RAGE promyogenic and anti-proliferative
signaling (Fig. 9B). Thus, S100B and HMGB1, which both are
damage-associated molecular pattern factors [3,14,15], might
physiologically regulate the regeneration of injured muscle tissue
with different mechanisms depending on their respective local
concentration and myoblast density. Whether S100B also activates
satellite cells in injured skeletal muscles remains to be investigated.
Materials and Methods
Expression and Purification of S100B
Recombinant bovine S100B, that is 97% identical to mouse
S100B, was expressed and purified as reported [41,42]. The
S100B concentration was calculated using the molecular mass of
the S100B dimer (21 kDa).
Preparation of Conditioned Media from Injured Skeletal
Muscle Tissue
Injury of C57BL/6 (Charles River) mouse muscles was
performed by BaCl2 injection [43] in Tibialis anterior muscle of 8-
wk old mice, under zolazepam/tiletamine anesthesia. Briefly,
50 ml of an aqueous 1.2% (w/v) BaCl2 solution were injected along
the whole length of left Tibialis anterior muscles. Controlateral
muscles were injected with vehicle and used as controls. After
different recovery times (1–14 days) the animals were sacrificed
and Tibialis anterior muscles were removed and incubated in
phosphate-buffered saline (0.15 ml/muscle) for 2 h at 4uC under
agitation [44]. The conditioned media (CM) so obtained were
trichloroacetic acid-precipitated [45] for detection of S100B,
bFGF and HMGB1 by Western blotting. After CM collection,
muscle tissue was homogenized in Laemmli buffer (0.4 ml/muscle)
and subjected to Western blotting to detect RAGE and FGFR1.
See Text S1 for double Pax7/RAGE immunofluorescence.
Approval of use of animals was obtained by the Ethics Committee
of the Perugia University and the Ministero della Salute, Italy.
Cell Culture Conditions
C2C12 and primary myoblasts seeded at a low density (LD,
,8610
3 cells/cm
2) or high density (HD, ,32610
3 cells/cm
2),
were cultured for 24 h in Dulbecco’s modified Eagle medium
(Invitrogen) supplemented with 20% FBS (Invitrogen), 100 U/ml
penicillin, and 100 mg/ml streptomycin (GM), in a H2O-saturated
5% CO2 atmosphere at 37uC and then shifted to Dulbecco’s
modified Eagle medium containing 0.5% horse serum (DM) to
induce myoblast differentiation. C2C12 and primary myoblasts
were cultivated in DM in the absence or presence of either S100B,
bFGF (Peprotech) or HMGB1 plus or minus other additions as
indicated in figure legends. Details of myoblast treatment after
24 h in DM are given in legends to pertinent figures.
Isolation of Primary Myoblasts
Rage
2/2 mice generated as described [46] were obtained from
Angelika Bierhaus (Heidelberg, Germany). Primary myoblasts
were isolated from 3-d-old WT C57BL/6 or Rage
2/2 pups,
cultivated as described [47] and characterized by immunofluores-
cence using a polyclonal anti-Met antibody (1:50, Santa Cruz
Biotechnology) after fixation with cold methanol for 7 min at
220uC. Greater than 95% cells were Met-positive.
Cell Proliferation
Cell proliferation was measured by a bromodeoxyuridine
(BrdU) incorporation assay. BrdU was added to cultures 2 h
Figure 9. Proposed schematics of S100B/RAGE and RAGE/S100B/bFGF/FGFR1 interactions in LD and HD myoblasts and of action of
released S100B following skeletal muscle injury. (A) (Left) In LD myoblast cultures S100B tetramers/octamers promote RAGE oligomerization
and/or stabilization of RAGE oligomers resulting in the simultaneous stimulation of proliferation and activation of the myogenic program; this occurs
irrespective of the absence or presence of bFGF. At high concentrations, high-order S100B oligomers bind bFGF and the S100B/bFGF complex cross-
links RAGE and FGFR1 on the same cell. This results in enhancement of FGFR1 signaling and blockade of RAGE signaling likely due to lack of RAGE
oligomerization and/or stabilization of RAGE oligomers. However, in the absence of bFGF either low or high S100B engages RAGE. (Right) In HD
myoblast cultures, S100B tetramers/octamers bind bFGF and the S100B/bFGF complex cross-links RAGE and FGFR1 on apposed cells resulting in
blockade of RAGE signaling likely due to lack of RAGE oligomerization and/or stabilization of RAGE oligomers and enhancement of FGFR1 signaling.
This results in stimulation of proliferation and inhibition of differentiation. (B) Early after injury S100B mainly engages RAGE on activated satellite cells
thereby stimulating their proliferation and activating the myogenic program. Whether S100B activates satellite cells remains to be investigated (?).
During the proliferation phase S100B binds to both, RAGE and bFGF/FGFR1 and promotes the formation of a RAGE/S100B/bFGF/FGFR1 tetracomplex
thereby stimulating myoblast proliferation and blocking RAGE [9]. At this stage HMGB1 might compete with S100B for binding to RAGE thereby
unlocking RAGE and stimulating its promyogenic activity [12]. Later on, with diminishing S100B levels RAGE would be activated by HMGB1 thereby
promoting myoblast differentiation and myocyte fusion into myofibers.
doi:10.1371/journal.pone.0028700.g009
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immunofluorescence using a monoclonal anti-BrdU antibody
(1:50, Santa Cruz Biotechnology). BrdU
+ and total cells were
counted.
Western Blotting
Myoblasts were lysed and cell lysates were subjected to Western
blotting as described [10] using the antibodies listed in Text S1.
Where required, culture media were collected and trichloroacetic
acid-precipitated [45]. The pellets were resuspended in Laemmli
buffer and subjected to Western blotting using anti-bFGF
antibody. The immune reaction was developed by enhanced
chemiluminescence (SuperSignal West Femto Maximum or
SuperSignal West Pico, both from Pierce).
Immunocytochemistry
MyHC was detected by immunocytochemistry as described
[10].
Reverse Transcription-PCR
Total RNA was extracted from C2C12 myoblasts using the
TRIzol reagent (Invitrogen) according to the manufacturer’s
instructions. The following primers were used: murine myogenin
59-GCTGTATGAAACATCCCCCTA-39 and 59-CGCTGT-
GGGAGTTGCATT-39 (denaturation at 94uC for 1 min, anneal-
ing at 56uC for 30 sec, extension at 72uC for 30 sec).
Co-immunoprecipitation
C2C12 and primary myoblasts cultivated for 30 min in DM in
the absence or presence of S100B were lysed in buffer containing
50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100,
1 mM CaCl2, 10 mM NaF and 1 mM sodium orthovanadate in
the presence of a mixture of protease inhibitors (Roche Applied
Science). Solubilized proteins were subjected to immunoprecipi-
tation using either a polyclonal anti-S100B antibody (SWant,
2 mg/mg total protein), a polyclonal anti-RAGE antibody (Santa
Cruz Biotechnology, 2 mg/mg total protein), a monoclonal anti-
FGFR1 antibody (Chemicon, 2 mg/mg total protein), a polyclonal
anti-bFGF antibody (Santa Cruz Biotechnology, 2 mg/mg total
protein) or non-immune IgG. Immunoprecipitates were probed
with the following antibodies: polyclonal anti-S100B antibody
(1:1000, Epitomics), polyclonal anti-RAGE antibody (1:1000,
Santa Cruz Biotechnology), monoclonal anti-FGFR1 antibody
(1:1000, Chemicon), polyclonal anti-bFGF antibody (1:1000,
Santa Cruz Biotechnology), polyclonal anti-c-Met antibody
(1:500, Santa Cruz Biotechnology).
Neutralization of Ligands or Receptors
Myoblasts in DM were treated for 2 h with either polyclonal
anti-RAGE antibody (10 mg/ml, Santa Cruz Biotechnology) or
monoclonal anti-FGFR1 antibody (2 mg/ml, Chemicon) and
cultivated for 24 h in the absence of additions or presence of
S100B. In experiments of effects of neutralization of culture
medium bFGF, monoclonal anti-bFGF antibody (5 mg/ml, clone
bFM-1, Millipore) was added to myoblasts in DM for 2 h followed
by treatments as described in figure legends. Control samples
received non-immune IgG.
In situ Proximity Ligation Assay
To investigate whether S100B interacts with bFGF, FGFR1
and/or RAGE we also used in situ proximity ligation assay (PLA),
which allows the visualization of subcellular localization and
protein-protein interactions in situ [34]. See Text S1 for details.
Statistical analysis
Each experiment was repeated at least three times. Represen-
tative experiments are shown unless stated otherwise. The data
were subjected to analysis of variance (ANOVA) with SNK post
hoc analysis using a statistical software package (GraphPad Prism
version 4.00, GraphPad Software, San Diego, CA, www.
graphpad.com). Where appropriate data were represented as
averages of 3 determinations 6 SEM. Statistical significance was
assumed when p,0.05.
Supporting Information
Figure S1 Short-term treatment of LD mouse primary myo-
blasts with S100B results in enhanced myogenin expression and
myotube formation after S100B washout. (A) LD primary
myoblasts were cultivated in DM in the absence or presence of
S100B for 24 h, washed and cultivated for another 24 h in DM
with no additions. Myoblasts were lysed and cell lysates were
subjected to Western blotting for detection of myogenin. (B) Same
as in A except that LD myoblasts were viewed by phase-contrast at
48 h after washout. Bars=250 mm (100 mm in insets).
(TIF)
Figure S2 Detection of S100B and bFGF in culture media. (A)
Immunoprecipitation of S100B in LD myoblast cultures in the
absence or presence of added S100B. C2C12 myoblasts cultivated
for 30 min in DM in the absence (C) or presence (S100B) of 1 nM
S100B were lysed in buffer containing 50 mM Tris-HCl (pH 7.4),
150 mM NaCl, 1% Triton X-100, 1 mM CaCl2, 10 mM NaF
and 1 mM sodium orthovanadate in the presence of a mixture of
protease inhibitors (Roche Applied Science). Solubilized proteins
were subjected to immunoprecipitation using a polyclonal anti-
S100B antibody (SWant, 2 mg/mg total protein). Inputs (In) and
immunoprecipitates (IP) (20 mg protein each) were subjected to
Western blotting using an anti-S100B antibody. (B) bFGF is found
in culture media of LD myoblasts. C2C12 myoblasts were
cultivated for 30 min in DM with no additions (control, C) or in
the presence of added S100B (1 nM), and culture media were
collected and trichloroacetic acid-precipitated. The pellets were
resuspended in Laemmli buffer and subjected to Western blotting
using anti-bFGF antibody. Purified bFGF (10 ng) was loaded on
lane M.
(TIF)
Figure S3 Short-term treatment of LD C2C12 myoblasts with
HMGB1 results in stimulation of proliferation and activation of
the myogenic program. Myoblasts were cultivated in DM in the
absence or presence of HMGB1 for 24 h, washed and cultivated
for another 24 h in DM with no additions. (A–C) During the first
24 h of treatment HMGB1 activated ERK1/2 and p38 MAPK
(A), stimulated proliferation (B) and activated the differentiation
program (C). (D) At 48 h after washout HMGB1-treated myoblasts
expressed higher MyHC levels than untreated myoblasts. (E)
Myoblasts were cultivated in DM in the presence of HMGB1 for
30 min and processed for immunoprecipitation using an anti-
HMGB1 antibody. RAGE, but not FGFR1 co-immunoprecipi-
tated with HMGB1.
(TIF)
Figure S4 S100B upregulates either RAGE or FGFR1 expres-
sion in LD myoblasts depending on the concentration. (A)L D
myoblasts were cultivated in DM for 24 h in the presence of
increasing S100B concentrations and subjected to Western
blotting using anti-FGFR1 or anti-RAGE antibody. (B) Myoblasts
pretreated (2 h) with 10 mg/ml anti-RAGE antibody or 2 mg/ml
anti-FGFR1 antibody were cultivated in DM for 24 h in the
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blotting using anti-RAGE antibody or anti-FGFR1. Controls
received 10 mg/ml non-immune IgG. *Significantly different from
control (n=3).
(TIF)
Text S1 Supplementary materials and methods. Double Pax7/
RAGE Immunofluorescence. Tibialis anterior muscles were
removed from uninjured mice and from injured mice at day 3
after injection with BaCl2, fixed in 4% formalin in tris-buffered
saline (TBS) (pH 7.2), dehydrated and paraffin embedded.
Paraffin sections were cut at 4 mm, deparaffinized with xylene,
rehydrated in a graded ethanol series. Sections were washed with
TBS, pH 7.4, incubated for 1 h with Blocking Buffer (BB, 0.4%
Triton-X-100, 10% donkey serum and 1% bovine serum albumin
in phosphate-buffered saline) and then probed with the following
primary antibodies in BB (1:20): goat polyclonal anti-RAGE
(Santa Cruz Biotechnology), mouse monoclonal anti-Pax7 (R&D
Systems). The secondary antibodies were donkey anti-mouse
Alexa Fluor 488-conjugated (Invitrogen), donkey anti-goat Alexa
Flour 594-conjugated (Invitrogen), and goat anti-rabbit rhoda-
mine-conjugated (Sigma Aldrich). Western Blotting. Myoblasts
were lysed and cell lysates were subjected to Western blotting as
described (10). The following antibodies were used: monoclonal
anti-MyHC (1:1000, Novocastra), monoclonal anti-M-cadherin
(1:1000, Santa Cruz Biotechnology), polyclonal anti-caveolin-3
(1:1000, BD Transduction Laboratories), monoclonal anti-a-
tubulin (1:10000, Sigma), polyclonal anti-phosphorylated
(Thr180/Tyr182) p38 MAPK (1:1000, Cell Signaling Technolo-
gy), polyclonal anti-p38 MAPK (1:2000, Cell Signaling Technol-
ogy), polyclonal anti-phosphorylated (Thr202/Tyr204) ERK1/2
(1:2000, Cell Signaling Technology), polyclonal anti-ERK1/2
(1:20000, Sigma), monoclonal anti-myogenin (1:1000, Santa Cruz
Biotechnology), anti-S100B (1:1000, Epitomics), polyclonal anti-
RAGE antibody (1:1000, Santa Cruz Biotechnology), monoclonal
anti-FGFR1 antibody (1:1000, Chemicon), polyclonal anti-bFGF
antibody (1:1000, Santa Cruz Biotechnology), polyclonal anti-c-
Met antibody (1:500, Santa Cruz Biotechnology), and monoclonal
anti-p-Tyr (PY20) sc-508 (1:1000, Santa Cruz Biotechnology). For
analyses of culture medium bFGF, culture media were collected
processed as described [17]. Pellets were resuspended in Laemmli
buffer and subjected to Western blotting using anti-bFGF or anti-
HMGB1 antibody (1:1000, R&D Systems). In Situ Proximity
Ligation Assay. Myoblasts in differentiation medium were
pretreated with polyclonal anti-S100B (50 mg/ml, SWant),
monoclonal anti-bFGF antibody (5 mg/ml, clone bFM-1, Milli-
pore) or non-immune IgG (50 mg/ml) for 2 h before incubation
with 1 nM S100B or vehicle for 30 min. Cells were then fixed as
described [10], treated with a mixture of either anti-RAGE and
anti-FGFR1 antibodies, anti-S100B and anti-bFGF antibodies,
anti-S100B and anti-FGFR1 antibodies or anti-S100B and anti-
RAGE antibodies, and subjected to in situ PLA [34] (OLINK
Bioscience, Uppsala) according to the manufacturer’s instructions.
In control experiments anti-RAGE antibody, anti-FGFR1 anti-
body, anti-S100B antibody or anti-bFGF antibody was omitted.
Skeletal muscle tissue from uninjured and injured mice was
subjected to in situ PLA using anti-S100B/anti-RAGE antibody
pairs or anti-RAGE/anti-FGFR1 antibody pairs. Complex
formation between RAGE and FGFR1 was taken as representa-
tive of RAGE/S100B/bFGF/FGFR1 complex formation (see [9]
and Fig. 6H).
(TIF)
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